Article

CURE wins awards because of you

We've had readers tell us that they've been reading CURE for years. They may have picked up the magazine at their first visit to the oncologist, read CURE during their chemotherapy infusions and then subscribed to the magazine when they finished treatment, passing their issues along to friends and family who may have been diagnosed after them. And throughout that journey, you've steadily let us know what's important to you. We've received so many letters and e-mails suggesting article ideas, telling us what you like and what you don't like, telling us what stories we've nailed and what we missed (we appreciate that, too!). You've shared beautiful, heart-breaking and very personal stories of your cancer journeys. That's why when CURE won three FOLIO magazine awards this past week, we knew it was because of you, and we wanted to share this honor with you, our readers.CURE placed first in the health/fitness consumer magazine full issue category for our Spring 2010 issue and for best health/fitness consumer magazine website. The Winter 2009 cover won third for best consumer magazine cover (with 250,000-plus circulation). Thank you.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.